Lennart hello, joining. you everyone. for Thank Thank you, and
strategy has making with update our presented our As will June Investor and progress on the we're I core Lennart the some on updates Event. on business business said a implementing start also at
going relates those also to our we the the end to and we one will plan two forward, and COVID then outlook growth, with of that for and with course, company and Rene review, the Q&A. elements it As in how address future the to financial business will be featured power plan restructure
So, QX.
Our our QX progress performance outlined meaningful as priorities, in Event. we strides business core our reflects making execution, which on Investor strategic
for quarter. are solid we development. data-driven to and quarter, is we mentioned, At reinventing we grew last delivering In QX last continuously and As where revenue core expanding saw our see business, year. Diagnostics versus the consecutive XX% drug the this second segments business growth which performance, approach core together discovery Pharma our
We see that are growth. very to to business is core happy back
testing we're have COVID a our in core revenues landscape in proactively, is are did in Diagnostics, we overall previously. our acting including communicated which to COVID-XX and not shift to business While Pharma seeing line top line, contribute are continue over what efforts testing focused on and
Please next more detail increase This six. in bit new having individuals business a segment years. that in turn X XX,XXX our Bio/Databank Bio/Databank million to steady discuss slide of rare for we of couple what's Foremost, to our now in about demonstrate deal diseases. goal our to will our our diagnostics close we're observed to added superior the continued a is QX. I diagnostic commitment core the the expanding patients and In segments. period to business offerings approximately excited of
previous XX% core revenue XX% order can in Here specifically on intake quarter. the segment, the mentioned see up over of the our Diagnostics More on reported graph in QX business. you the we XX,XXX,
growth, the business seen up we segment the XX% Within returned have to year-over-year.
segment Diagnostics with the these value in our the diseases nice return, we've we rare growth. diagnostic to covering business for and with We believe propositions it's ranging see the offer the quarter widest last globally, quarters, indicated teams trends fifth unique We portfolio testing broadest of have currently consecutive had.
Turning Pharma to segment. our
We Diagnostics business Pharma have revenues recovery year-over-year. down compared seen segment. as segment to experiencing the attractive
have of as a results translate the revenues. highlighted a in from of to that it's past, until mostly timing a relates we new it signing As partner the revenues pharma contract the with issues into delayed contract
collaborations, have However, advanced we revenue started active generations. towards and in recent ones they're now XX XX all new quarters
back we that later I to that are details seven. business share will some to QX. so growth, And with confident pharma the slide starting on on. return quite will further turn Please
the business of versus bulk order cell progress our The at core look and driven lines. diagnostics period was sample primarily knowledge of includes by Pharma, XX%. XX% [ph]. This in where making our intakes Diagnostics Overall, growth in Pharma our Here, the and units, business number Bio/Databank, repository. increase XXXX, up well contributed were requests which as test same growing on in as samples we're data is
the repository. number in individuals see you right, our the on graph of the On data
and we added XX,XXX individuals of our Bio/Databank rare believe discovery revolutionizing database. core differentiation XXXX, the of course about for basis of rare diseases. development the the Over the new our eventually be our disease-centric our We to will and
or tier, metric. forward. we newly a going content as some As previous our patients truly have at of to in the look first event shared the has we stayed its system. proposed data our And strengthened, a summary review into Bio/Databank backs by governance, by growing well that so and CDO you the and to in an it Goerner plan keep past, improves will a years, to the upgrade to upgrade a databank. at stated [ph] we some the that Bio/Databank. At imagine quarters, based our EQ up that share updates Bettina we databank. good time deeper initiative the we the Officer insights databank, by then strategic. few on setting In communicated cleaned It's sure insights number right and in June, the making can defined Data XXXX watch science to up insights six how a in run way our in mind and investor This approach It's the is as what's the devices now
As in XXX,XXX. of active samples our XXX,XXX about QX, end about the approximately of today, have XXth, speak repository. At patients -- we patients November we and
is ability you more and mine Bio/Databank, we we really Some communicated had will that and already there number of improved, of ensuring come reclassification now XXX,XXX it but we robust insights. the the that the review, remember quality recent the have to after have the with needed is of however, cleanup about of to number, that what in previously, and up
provide with some going as metrics to growth Turn we and more of the eight. to Bio/Databank. the it slide relates also Additionally, you to are content now the
more believe, we how You can of the see databank and we details, develop the in progressing what's metrics some going forward. it's that show
We have total discussed. number of results, course, as of previously
Bio/Databank, spots, that's sample blood in but dried go much us back also analysis. the that the so have We that it's blood samples and is do stored further to to why and data, the dried our databanks allow
We have of number versus have data done just genome for the full that example. and panel sequence gene exome we
is discovery that percentage future side And, efforts. Cell potential, that food on to for have discovery our allows network important of is access getting patients. data this an This future are of us in to engage work lines. critical lines built hospitals all and position. with we course, cell active just physicians the also use content of the for samples with have or research. diagnostics, a for that of pharma to also them. our for commercialize course, and not and us on Then We research And the the we
in appreciate you relevance You recent of the way the we're of forward. this can number developed more now the the value slide is nine. databanks quarter. Please we detailed that slide better to on turn we've -- do plan We this, With the forward. to going value see the also believe how to going a also for details -- providing and here and
you area. an And relates can It in see of reflected we closer have neurological data that these Here is partners number strong to that and established areas. metabolic metabolic it also segment there, this is of in look, in have and in increasing terms samples you a diseases. and as -- pharma particularly
research, Please turns think but the space. and we'll partnerships XX. I underlying while in why We've slide partnerships, small shown our something slide we'll believe that with future. again, a highlight shown just Those however, a disease be would event, that at And, will revenue. research are rather we revenue start which As may our question small specific nature. collaboration partnerships the we of relatively the The by may believe is contribution, we're the it that like collaborations revenues. in discovery positioned or and grow progresses, to initial we we expand most these have, in in research uniquely low June have rare the so drug
them, data that Here are insights add we we driven space differentiate the are and some from unique believe and companies competitives. in also clearly
competitive complete And and brands in have are years We network rare a have side collecting disease We advantages. had has samples we filled XX started disease insights rare XX the with company. and and over one years.
do have companies the more that recently expressed brand have it. other in but diseases, those nor rare the can they not also of Some repository bandwidth, the interest do
us Secondly, I footprint also our want unique. highlight that makes to geographic
business. Of if a the good, presence revenues it highly diagnostic especially have a in is to course, commercial it U.S., relates valuable to strong from
what nature, a for footprint we is in overall, the Rare challenge, insight and and global patient global our and to mind is However, required, critical rare believe right data that's patient global our generate diseases. by absolutely a collect are and data have. for diseases sufficient footprint we geographic
enable -- Bio/Databank business omics tools using orphan to our identification, and support, generate is Bio/Databank, clinical to go discovery a discovery our least, discovery, for trial business services, patient This last superior diagnostics, that core. to clinical And remind patient centric remind to rare me platform a not the our for disease drug with model but XX. space. AI Let's for and to you and insights slide in our of at model, develop drug pharma
to I So let's progress. this highlight quarter. slide continuing want few along, what in XX. is a we the done recent updates to go Scientific just have
find impact pharma we and what we Our discovery. in footprint, have diagnostic in
So XX. with let's start slide
As we a to Medicine. around in tried want at diseases Sea scientific a quarter, the to course, we'll number have space. sure attractiveness disease over patients translate as I of Red disease is here utilized We study believe course, they publications our the the just you've a commitment Bio/Databank covered. our of and of rare we highlight and those, here. you of contribution you our know, our And scientific and world. Journal by and core efforts recent of in of know rare presented these that all Taking are depth better of understanding rare look at Bio/Databank. highlight have data revenues the Not a in seen expertise, leading the one for recent our give that sure, to as partner the I'm need to we closer presents the
Children's international find team, the understanding analyzed And for pharmacological a syndromic of including Medicine, create data that medical way Rady Our that Institute birth and to range the treatment condition. Genomic -- a structural deeper have to of unique advanced families to on paves for A*STAR defects.
offering huge every into Now potentially year for deliver the a disease, that method rare sequence what approaches rare custom product Slide partner, highlights has find but for with research Diagnostics to opportunity we for for in find actually development. Together powered announced. birth combine multiple with our date collaborate, of also We recently for XX on assay pharmaceutical disease develop to why signed exciting with X teams what born programs, and expertise, them estimates have and with cost Twist institutions, databank, The create translate Clinical an translates CENTOGENE will offers clinical business, and Bioscience you assays. think million robustness, commercialize organizations it are by defects. a infants translate, academic findings capitalize treatments such if kits this Bioscience developers just and genetic not and our the that drug can such to partnership will the our into and almost to to insights Bio/Databank unique new Twist and we been had to drug are manufacturing be demonstrated of diagnostics. that
genetic deliver that the development, diagnostic ongoing be We to top area. for with offering more year. rapid next testing of decentralization belief a This kicked to plan the enables our in next by off making will reliable of quality collaboration, the and for together followed and It on this milestone have with commercial are laboratories a patients. pivotal to decentralized FTD the and will solutions us is partner genetic role rare address collaboration launch the major progress excited play help trends accessible, testing disease
there months. some related We our efforts our on the product announcements progress around CentoCloud coming in expect also the offering of
progress are confident partnerships I is and at really revenue Pharma that Pharma Now taking recovery on side, Diagnostics had let's than look that there. our we time in to more XX. that mentioned are track slide we with recent but get the
So, you announced XXXX, early signed that. in have the I partnership we want that highlight is Alector. deal have to here We and with
We have just side. an scale patients X,XXX enrollment I a weeks for think of now started X,XXX ago exciting from that our couple large study few patient a it's highlights study. things to And that
team working able with advantage look -- in are competitive that revenues to those the a to who build similar Bio/Databank, overall, temporal associated collaborations in XXXX. have can course, the customers future our And cohort start us this patients mind be generated things right patients, we that or a And interest that next us time us that seeing CENTOGENE here, of will actually number of to disease these to our sort signed has of we the key patients through our date year. example, space. rare such and and have contracts, had multiple dementia Denali new the in, that. do of that First company of for what all, to up insights also with rolled with we while takes what the of partnership Bio/Databank. contracts unique and the quite in the we was help signing But highlights from and rare business that when the the contract And disease accumulated the to actually in be that accelerate highlights high enrollment patients finding for it of are a frontal model at for neurological are customers mostly it's value actually diseases with allows sign the the can and
that be So volume for we some of keep growth you had just started on Please sure that's QX, these to return results the think signed, pharma that in slide a large not track. confidence, Alector basis, that also we back to new XX. contracts we'll
the Bio/Databank our avatars. to like how for partnerships we a plan efforts use Just I development discovery short going of update rare and to on forward. our and discovery would our diseases focus us cure we our I have mentioned the enable to be efforts And diseases coming these in able rare in June the our you, event and years. think aspiration to the and to for on
So, sure boards structure team with You with term that accelerate avatar? What the digital the body regard. fully some progress have in typical developed can is exactly a [ph] heard on disease the the accelerate potential digital swing works may swing that of use. do work copy physicians and and have we made work to that we that Patrice, has make quite to
Parkinson's three derived enable for and by a of and three pharmaceutical and actually be avatar and have make the his models initiative and avatar the who ultimately and our partner -- in value our models patients potentially better drug we is the those candidates to Patrice would and enables cell on around we I disease we excitement At to with practice be XX this then milestone. that start the diagnosed virtually we or maybe the think stop treated, example, to accelerate test psychology we to will avatars diversity and with Scientific up to the and progress of the is and to platform think like on And have disease have like focus were validating have current this able model by we patient, can using done diseases, on that rare on and and at coming And a used key avatar better certain disease least and have take recapitulate that complete. humans three already value. avatars, that avatar so And of a how when by to the insignificant develop clearly data as you last anatomy cell avatars in a avatar. the above to place, to or on hands will part in Chief these our partners. Gaucher have we models a a really We cell and come actually as the to model. an an disease can linked whole we impacts digital to XX, which course, apart up disease that be model the the hundred also leads from a real forefront All to the least on on understanding the researchers once whole CENTOGENE data, And genetic on threes, testing and some who a priority we Niemann-Pick actual disease We, and the For we pass hundred, Denefle, module, approach be rare disease to generate as be call. date how disease introduced that of are this, And to to disease to, those models. enough aspiration at potentially make that Officer, to train insights the with quarters. know, that in a exceeded we won't a initiatives patients such such need drive strength patient treatment we hypothesis we with hundred generate of opportunity the us earnings never hypothesis our mind could believe on the the those before. short-term surgery our
of course, the We accelerate range the our And of stop our we not in three, the next and strategy, that would over work to we and to on those have progress the on and business come. to With prioritize core a will, on hand overall diseases to on update success like make that years of we Rene. there. planned few I to
